Morningstar

Cellectis SA ALCLS

Morningstar Rating

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety

GlobeNewswire Sep 3, 2024 8:30pm
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors

GlobeNewswire Aug 26, 2024 8:30pm
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

GlobeNewswire Aug 7, 2024 6:00am
Cellectis Provides Financial Results for the Second Quarter 2024

GlobeNewswire Aug 6, 2024 8:30pm
Cellectis Gets Orphan Designation for Drug Used in Cancer Treatment

Global News Select Aug 1, 2024 10:02pm
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment

GlobeNewswire Aug 1, 2024 8:30pm
Cellectis: FDA Gives Orphan Drug, Rare Pediatric Status to Leukemia Treatment

Global News Select Jul 25, 2024 9:53pm
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

GlobeNewswire Jul 25, 2024 8:30pm
AMD, Kraft Heinz stocks surge, WeWork and CVS shares sink and other stocks on the move

MarketWatch Nov 1, 2023 5:55pm
Cellectis Shares Soar Premarket on AstraZeneca Deal

Global News Select Nov 1, 2023 11:36am
Cellectis' stock is the biggest gainer and most active premarket after equity investment, collaboration pact with AstraZeneca

MarketWatch Nov 1, 2023 11:29am
AstraZeneca to Invest $245 Million in Deal With Cellectis

Global News Select Nov 1, 2023 8:02am

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.